133 related articles for article (PubMed ID: 8471553)
1. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers.
Silvestrini R; Daidone MG; Del Bino G; Mastore M; Luisi A; Di Fronzo G; Boracchi P
Ann Oncol; 1993 Mar; 4(3):213-9. PubMed ID: 8471553
[TBL] [Abstract][Full Text] [Related]
2. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy.
Silvestrini R; Daidone MG; Mastore M; Di Fronzo G; Coradini D; Boracchi P; Squicciarini P; Salvadori B; Veronesi U
J Clin Oncol; 1993 Jun; 11(6):1150-5. PubMed ID: 8501501
[TBL] [Abstract][Full Text] [Related]
3. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer.
Meyer JS; Province MA
Cancer; 1994 Oct; 74(8):2287-99. PubMed ID: 7922981
[TBL] [Abstract][Full Text] [Related]
4. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.
Pinto AE; André S; Soares J
J Clin Pathol; 1999 Aug; 52(8):604-11. PubMed ID: 10645231
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of DNA ploidy in 653 Japanese women with node-negative breast cancer.
Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
Int J Clin Oncol; 2001 Aug; 6(4):177-82. PubMed ID: 11706555
[TBL] [Abstract][Full Text] [Related]
6. 3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer.
Silvestrini R; Daidone MG; Valagussa P; Di Fronzo G; Mezzanotte G; Mariani L; Bonadonna G
J Clin Oncol; 1990 Aug; 8(8):1321-6. PubMed ID: 2380758
[TBL] [Abstract][Full Text] [Related]
7. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
8. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer.
Silvestrini R; Daidone MG; Luisi A; Boracchi P; Mezzetti M; Di Fronzo G; Andreola S; Salvadori B; Veronesi U
J Clin Oncol; 1995 Mar; 13(3):697-704. PubMed ID: 7884430
[TBL] [Abstract][Full Text] [Related]
9. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.
Silvestrini R; Benini E; Veneroni S; Daidone MG; Tomasic G; Squicciarini P; Salvadori B
J Clin Oncol; 1996 May; 14(5):1604-10. PubMed ID: 8622078
[TBL] [Abstract][Full Text] [Related]
10. Autoradiographic and flow-cytometric assessment of cell proliferation in primary colorectal cancer: relationship to DNA ploidy and clinico-pathological features.
Costa A; Faranda A; Scalmati A; Quagliuolo V; Colella G; Ponz de Leon M; Silvestrini R
Int J Cancer; 1992 Mar; 50(5):719-23. PubMed ID: 1544705
[TBL] [Abstract][Full Text] [Related]
11. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.
Wenger CR; Beardslee S; Owens MA; Pounds G; Oldaker T; Vendely P; Pandian MR; Harrington D; Clark GM; McGuire WL
Breast Cancer Res Treat; 1993 Oct; 28(1):9-20. PubMed ID: 8123871
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinomas--a 10 year survival study.
Ewers SB; Attewell R; Baldetorp B; Borg A; Fernö M; Långström E; Killander D
Breast Cancer Res Treat; 1992; 24(2):115-26. PubMed ID: 8443399
[TBL] [Abstract][Full Text] [Related]
13. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers.
Silvestrini R; Daidone MG; Benini E; Faranda A; Tomasic G; Boracchi P; Salvadori B; Veronesi U
Clin Cancer Res; 1996 Dec; 2(12):2007-13. PubMed ID: 9816160
[TBL] [Abstract][Full Text] [Related]
14. Oestrogen and progesterone receptor expression influences DNA ploidy and the proliferation potential of breast cancer cells.
Andronas M; Dlay SS; Sherbet GV
Anticancer Res; 2003; 23(3C):3029-39. PubMed ID: 12926157
[TBL] [Abstract][Full Text] [Related]
15. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens.
Dressler LG; Seamer LC; Owens MA; Clark GM; McGuire WL
Cancer; 1988 Feb; 61(3):420-7. PubMed ID: 3338012
[TBL] [Abstract][Full Text] [Related]
16. DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials.
Witzig TE; Ingle JN; Schaid DJ; Wold LE; Barlow JF; Gonchoroff NJ; Gerstner JB; Krook JE; Grant CS; Katzmann JA
J Clin Oncol; 1993 Feb; 11(2):351-9. PubMed ID: 8426213
[TBL] [Abstract][Full Text] [Related]
17. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.
Silvestrini R; Veneroni S; Daidone MG; Benini E; Boracchi P; Mezzetti M; Di Fronzo G; Rilke F; Veronesi U
J Natl Cancer Inst; 1994 Apr; 86(7):499-504. PubMed ID: 8133533
[TBL] [Abstract][Full Text] [Related]
18. Biological correlation between HER-2/neu and proliferative activity in human breast cancer.
Tommasi S; Paradiso A; Mangia A; Barletta A; Simone G; Slamon DJ; De Lena M
Anticancer Res; 1991; 11(4):1395-400. PubMed ID: 1684096
[TBL] [Abstract][Full Text] [Related]
19. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.
Pinto AE; André S; Pereira T; Nóbrega S; Soares J
Ann Oncol; 2001 Apr; 12(4):525-33. PubMed ID: 11398888
[TBL] [Abstract][Full Text] [Related]
20. [Flow cytometry detected S-phase fraction and ploidy as prognostic parameters in primary, node-negative breast cancer].
Winter K; Eidtmann H; Jonat W
Geburtshilfe Frauenheilkd; 1994 May; 54(5):291-4. PubMed ID: 8050690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
